The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Antibody-drug conjugates (ADCs) in NSCLC
Byoung Chul Cho, MD, PhD , Yonsei University College of Medicine in Seoul, Republic of Korea, Provides an overview of the mechanism of action of antibody-drug conjugates (ADCs), commenting on the activity of HER2-targeting ADCs in advanced-stage non-small cell lung cancer (NSCLC). ADCs have additionally shown encouraging activity targeting TROP2 in NSCLC in advanced-stage settings. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
